Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more
Apogee Therapeutics, Inc. Common Stock (APGE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.069x
Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) has a cash flow conversion efficiency ratio of -0.069x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.69 Million) by net assets ($903.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apogee Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Apogee Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apogee Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
easyJet plc
OTCQX:EJTTF
|
0.069x |
|
Sodexo SA
PA:SW
|
0.252x |
|
Lifco AB (publ)
PINK:LFCBY
|
0.103x |
|
Globalstar Inc
NYSE MKT:GSAT
|
0.091x |
|
Clear Secure Inc
NYSE:YOU
|
-0.285x |
|
Kontoor Brands Inc
NYSE:KTB
|
0.121x |
|
Meritage Homes Corporation
F:MEY
|
0.047x |
|
Jiangsu Nata Opto Electr Material
SHE:300346
|
0.059x |
Annual Cash Flow Conversion Efficiency for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $903.88 Million | $-227.45 Million | -0.252x | -5.37% |
| 2024-12-31 | $716.79 Million | $-171.17 Million | -0.239x | -21.35% |
| 2023-12-31 | $379.91 Million | $-74.76 Million | -0.197x | -70.20% |
| 2022-12-31 | $142.07 Million | $-16.43 Million | -0.116x | -- |